

1 **TITLE**

2 Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2  
3 antibody immunoassays

4 **RUNNING TITLE**

5 Low IgM/A specificity of commercial SARS-CoV-2 ELISA

6 **AUTHORS**

7 Rebeca Santano<sup>a#</sup>, Diana Barrios<sup>a</sup>, Fàtima Crispi<sup>b</sup>, Francesca Crovetto<sup>b</sup>, Marta Vidal<sup>a</sup>, Jordi  
8 Chi<sup>a</sup>, Luis Izquierdo<sup>a</sup>, Eduard Gratacós<sup>b</sup>, Gemma Moncunill<sup>a</sup>, Carlota Dobaño<sup>a#</sup>

9 **INSTITUTIONS**

10 <sup>a</sup>ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain  
11 <sup>b</sup>BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan  
12 de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona,  
13 Spain

14 **CORRESPONDING AUTHORS**

15 [rebeca.santano@isglobal.org](mailto:rebeca.santano@isglobal.org)

16 [carlota.dobano@isglobal.org](mailto:carlota.dobano@isglobal.org)

17 **ABSTRACT**

18 Serological diagnostic of the severe respiratory distress syndrome coronavirus 2 (SARS-  
19 CoV-2) is a valuable tool for the determination of immunity and surveillance of exposure to  
20 the virus. In the context of an ongoing pandemic, it is essential to externally validate widely  
21 used tests to assure correct diagnostics and epidemiological estimations. We evaluated the  
22 performance of the COVID-19 ELISA IgG and IgM/A (Vircell, S.L.) against a highly specific  
23 and sensitive in-house Luminex immunoassay in a set of samples from pregnant women and  
24 cord blood. The agreement between both assays was moderate to high for IgG but low for  
25 IgM/A. Considering seropositivity by either IgG and/or IgM/A, the technical performance of  
26 the ELISA was highly imbalanced, with 96% sensitivity at the expense of 22% specificity. As  
27 for the clinical performance, the negative predictive value reached 87% while the positive  
28 predictive value was 51%. Our results stress the need for highly specific and sensitive  
29 assays and external validation of diagnostic tests with different sets of samples to avoid the  
30 clinical, epidemiological and personal disturbances derived from serological misdiagnosis.

31 **KEYWORDS**

32 COVID-19; SARS-CoV-2; IgA; IgG; IgM; ELISA; Luminex; antibody; coronavirus; immunity;  
33 immunoassay; performance; sensitivity; specificity

## 34 INTRODUCTION

35 In the context of an ongoing pandemic, the importance of accurate diagnostic methods for  
36 disease control and elimination has been underpinned. Coronavirus disease 2019 (COVID-  
37 19) serological diagnostic based on antibody detection against the severe respiratory  
38 distress syndrome coronavirus 2 (SARS-CoV-2) is a valuable tool that allows for the  
39 determination of immunity development and surveillance of exposure to the virus (1,2). In the  
40 case of COVID-19, it is thought that antibodies mediate protection via a myriad of functions.  
41 (3). Therefore, good serological tests are required not only for epidemiological surveillance  
42 and policy implementation, but also for helping elucidate the mechanisms involved in  
43 protection and the susceptibility to reinfection after exposure to the virus (1,2). Additionally,  
44 serological tests may be also useful for establishing vaccine induced protection and finding  
45 blood donors that qualify to obtain plasma to be used as treatment for severe COVID-19  
46 patients (1,2,4).

47 The definition of a good serological test in terms of technical performance is based on the  
48 values of specificity (SP) and sensitivity (SE). The clinical relevance of a serological test is  
49 defined by the negative (NPV) and positive (PPV) predictive values. These last two  
50 parameters depend on the prevalence of the disease, while theoretically SP and SE do not.

51 Since achieving a high score of both SP and SE is generally difficult, prioritizing one of them  
52 during the test development process has personal, social and clinical implications, especially  
53 in the context of a pandemic where prevalence of disease might not be correctly defined.

54 Several antibody detection tests for SARS-CoV-2 are available in the market, such as rapid  
55 diagnostic tests (RDT), enzyme-linked immunosorbent assays (ELISA), neutralization  
56 assays, and chemiluminescent immunoassays (CLIA) (5). Here we compared the  
57 performance of a commercially available COVID-19 ELISA (Vircell Microbiologists, Granada,  
58 Spain) with the performance of an in-house fluorescence-based, high-throughput and  
59 multiplex Luminex immunoassay (6). The Vircell COVID-19 ELISA (from now on ELISA)  
60 detects specific IgG or IgM and IgA together (IgM/A) against the nucleocapsid (N) and spike

61 (S) antigens adsorbed on solid phase (7). The Luminex immunoassay has been optimized  
62 for the detection of specific IgG, IgM and IgA separately against a multiplex panel of 5  
63 antigens adsorbed on magnetic beads that are in suspension (6).

64 Thanks to the simplicity of the method and its automatization, ELISA is used in the clinical  
65 practice (8–11). Internal validation from Vircell, S.L. reports a 88% SE and 99% SP for IgM/A  
66 assay and a 85% SE and 98% SP for the IgG assay (7). External validation of widely used  
67 tests during this COVID-19 pandemic is essential to assure correct diagnostics and  
68 epidemiological estimations. We have previously reported that the in-house Luminex assay  
69 reaches up to 100% SP and 95.78% SE (6). Our aim is to report the performance of the  
70 ELISA IgG and IgM/A externally assessed using our highly specific and sensitive Luminex  
71 immunoassay.

## 72 **METHODS**

### 73 **Study population and sample selection**

74 We analyzed 283 samples from peripheral blood from pregnant women and cord blood  
75 (**Table 1**). Of those, 168 mothers belonged to a larger cohort of pregnant women whose  
76 samples were collected in the context of a study focused on the effects of COVID-19 on  
77 pregnancy outcomes. The study population and sample collection methods have been  
78 described elsewhere (12). The selection of samples in this report was based on the results  
79 obtained by ELISA and the suspicion of low SP by the IgM/A assay. In particular, it was the  
80 detection of 3 IgG and IgM/A positive tests in cord blood samples paired with mothers who  
81 had evidence of past and/or present infection that led to further investigation. While IgG  
82 crosses the placenta efficiently, a very limited amount of IgA passes from mother to fetus and  
83 IgM does not cross the placenta during normal pregnancies (13). As a result, the presence of  
84 an IgM/A positive test suggested congenital COVID-19 or false-positive results. Therefore,  
85 the selection included the aforementioned IgG+ and IgM/A+ cord blood samples (n= 3)  
86 together with IgG- and IgM/A- (n= 23), IgG+ and IgM/A+ (n= 22), and IgG- and IgM/A+ (n=

87 123) samples from pregnant women. The remaining samples were from healthy pre-  
88 pandemic pregnant women (n= 73) and cord blood (n= 39) (**Table 1**). Samples analyzed in  
89 this study received ethical clearance for immunological evaluation by the Review Board at  
90 each institution.

### 91 **ELISA IgG and IgM/A**

92 The IgG and IgM/A assays were performed as indicated by the manufacturer. Briefly,  
93 samples were diluted and, in the case of the IgM/A assay, they were then incubated with an  
94 IgG sorbent to eliminate IgG from plasma and any possible interference. Then, in both  
95 assays, samples and controls from the kit were incubated at 37°C for 45 min. After a washing  
96 step, they were incubated with peroxidase-conjugated detection antibodies (anti-human IgG  
97 or anti-human IgM+IgA) at 37°C for 30 min. After another wash, they were incubated with  
98 substrate solution for 20 min in the dark. Finally, stop solution was added and the optical  
99 density was read at 450 nm. The cut-off value was established based on the manufacturer's  
100 procedure. The ELISA IgG and IgM/A assays are based on the detection of specific  
101 antibodies against the N and S antigens adsorbed on a solid surface. Quantification is based  
102 on optical density after the reaction of the enzyme-linked secondary antibodies in contact  
103 with a substrate, and it is detected in a spectrophotometer.

### 104 **Luminex**

105 The in-house Luminex immunoassay has been optimized for the detection of specific IgG,  
106 IgM and IgA separately against a multiplex panel of antigens adsorbed on magnetic beads  
107 that are in suspension (6). Each magnetic bead region is characterized by a unique mix of  
108 two fluorochromes that allows their identification by laser excitation. Each antigen is coupled  
109 to a specific bead region and the multiplex panel included: the full-length N (N FL) antigen, a  
110 specific C-terminal region of N (N CT) (14), the full-length S, the subunit 2 from the S antigen  
111 (S2) and the receptor binding domain (RBD) in S1. Quantification is based on the detection  
112 of fluorescence emission by a phycoerythrin-labelled secondary antibody and it is detected in  
113 a Luminex FLEXMAP 3D instrument.

114 **RESULTS AND DISCUSSION**

115 **Moderate to high agreement between specific IgG measured by ELISA and Luminex**

116 Most of the IgG positive samples detected by ELISA were also classified as IgG positive by  
117 each of the antigens included in the Luminex panel (**Figure 1 and Table 2**), and many of the  
118 negative samples classified by ELISA were also classified as negative by each of the  
119 antigens included in the Luminex panel.

120 For IgG, the percentage of agreement ranged from 56.10% for N CT up to 93.10% for S2 for  
121 positive samples, and from 87.84% for N CT up to 98.61% for S2 for negative samples  
122 (**Table 2**). The antigen from the Luminex panel with the highest percentage of both positive  
123 and negative agreement for IgG was S2, which is part of the S antigens included in the  
124 ELISA.

125 Considering the classification obtained by the combination of IgG responses against all  
126 antigens included in the Luminex multiplex panel, the positive agreement was 54% while the  
127 negative agreement was 84.03% (**Table 2**). This resulted in 23 samples (all from mothers)  
128 with discrepancy for IgG: 1 sample Luminex negative and ELISA positive (LM-E+) and 22  
129 samples Luminex positive and ELISA negative (LM+E-) (**Figure 1 and Table 2**). Among  
130 these discrepant samples, 19 out of the 22 LM+E- samples were asymptomatic and either  
131 PCR negative or were not PCR tested, 1 sample was asymptomatic and PCR positive, 1  
132 sample was symptomatic 1-2 months prior to sample collection and PCR negative, and 1  
133 sample was symptomatic during the previous 7 days to sample collection and PCR positive.  
134 The only LM-E+ sample was asymptomatic and PCR negative. The 3 cord blood samples  
135 had concordant results between Luminex and ELISA. This most certainly reflects  
136 transplacental transfer of maternal IgG, since the 3 mothers had detectable levels of specific  
137 IgG detected by both tests and IgG is able to cross the placenta (13).

138 Since the in-house Luminex assay has previously been assessed and it demonstrated an  
139 excellent performance (6), we used the results obtained by Luminex as the gold standard to  
140 evaluate the performance of ELISA (**Table 3**). The usage of Luminex as gold standard is

141 further supported by the inclusion of several antigenic regions and three immunoglobulin  
142 isotypes that allow capturing a variety of immunological responses that cannot be attained by  
143 a PCR test, for example. Therefore, we evaluated the ELISA serological test based on a  
144 serological reference (Luminex) assay. For IgG, the SE was 55%, while the SP was 99%. As  
145 for the PPV and NPP, the percentages were 96% and 85%, respectively. Taking into account  
146 only the subjects with a PCR test done (N= 110), for IgG, the SE was 62%, while the SP was  
147 90%. As for the PPV and NPP, the percentages were 44% and 95%, respectively.

#### 148 **Low agreement between specific IgA/M measured by ELISA and IgA and IgM** 149 **measured by Luminex**

150 Almost all the IgM/A negative samples detected by ELISA were also classified as IgM or IgA  
151 negative by each of the antigens included in the Luminex panel, with 8 exceptions that  
152 correspond to 3 samples (**Figure 1 and Table 2**). On the contrary, although a proportion of  
153 IgM/A positive samples classified by ELISA were also classified as positive by each of the  
154 antigens included in the Luminex panel, many of them were classified as IgM or IgA negative  
155 by Luminex (**Figure 1 and Table 2**).

156 The percentage of agreement for positive samples ranged from 4.79% for N CT to 16.44%  
157 for N FL, and from 8.90% for N CT to 21.23% for S, for IgM and IgA, respectively. The  
158 percentage of agreement for negative samples ranged from 15.19% for S2 to 17.01 % for N  
159 FL and from 15.60% for S to 17.12% for N FL, for IgM and IgA, respectively (**Table 2**). In this  
160 case, the antigens from the Luminex panel with the highest percentage of both positive and  
161 negative agreement were N FL for IgM and N FL and S2 for IgA (**Table 2**).

162 Considering the classification obtained by the combination of all the antigens included in the  
163 Luminex multiplex panel, the positive agreement was 23.29% for IgM and 30.14 % for IgA,  
164 while the negative agreement was 17.65% for IgM and 17.74% for IgA (**Table 2**). As a  
165 consequence, there were 113 (LM-E+: 109 mothers and 3 cords; LM+E-: 1 mother) and 105  
166 (LM-E+: 99 mothers and 3 cords; LM+E-: 3 mothers) discrepant samples for IgM and IgA,  
167 respectively (**Figure 1 and Table 2**). Among the LM-E+ discrepant samples from mothers, 95

168 out of 109 for IgM and 86 out of 99 for IgA were asymptomatic and either PCR negative or  
169 were not PCR tested. For both IgM and IgA, 1 sample was PCR positive and asymptomatic,  
170 and the remaining discrepant samples were all symptomatic with either positive (N=3 for IgM  
171 and N=3 for IgA), negative (N=8 for IgM and N=7 for IgA) or not done PCR (N=2 for IgM and  
172 N=2 for IgA). The only LM+E- sample for IgM was asymptomatic and PCR negative. Among  
173 the 3 LM+E- samples for IgA there were 2 asymptomatic, one with a negative PCR and one  
174 without PCR, and 1 symptomatic with a negative PCR. The 3 cord samples had discrepant  
175 results. There were no detectable levels of specific IgM and IgA against any of the antigens  
176 measured by Luminex, while ELISA gave a positive result. The corresponding mothers were:  
177 1 LM+E+ for both IgM and IgA, 1 LM-E- for IgM and LM+E- for IgA, and 1 LM+E- for both  
178 IgM and IgA. In normal pregnancies, transplacental transfer of IgA is very limited and IgM  
179 does not cross the placenta (13), but in cases with severe infections significant levels of IgA  
180 and IgM can cross the placenta (15). In this study, none of the 3 mothers had severe COVID-  
181 19, which, together with the Luminex negative results, suggests that the results obtained by  
182 ELISA are false positive. However, vertical transmission of SARS-CoV-2 and the subsequent  
183 induction of immunoglobulins in the fetus should not be completely ruled out in cases of  
184 positive mothers, since transplacental transmission has been demonstrated in a severe  
185 COVID-19 pregnant case (16).

186 Regarding the performance of ELISA (**Table 3**) using Luminex results as gold standard, the  
187 SE was 97% for IgM and 94% for IgA, while the SP was as low as 18% for both IgM and IgA  
188 due to the many false positive results. As for the clinical performance parameters, PPV was  
189 23% for IgM and 30% for IgA, while the NPP was 96% for IgM and 88% for IgA. Regarding  
190 the performance of ELISA based on subjects with a PCR test done, IgM/A reached a 100%  
191 SE while the SP was as low as 23% due to the many false positive. As for the PPV and NPP,  
192 the percentages were 15% and 100%, respectively.

193 The vast majority of discrepant samples (LM-E+) were asymptomatic and either PCR  
194 negative or not tested. In other words, the pretest probability of infection was very low and  
195 supports the classification of these discrepant samples as false positive results. At the



196 moment, there is no recognized standard serological test to assess the sensitivity and  
197 specificity of other serological assays. Generally, neutralization assays and PCR test have  
198 been considered as the gold standard in other studies (17–23), but other assays such as  
199 CLIA have also been used (24). In this case, the use of PCR results as gold standard  
200 showed a very similar technical performance (SE and SP) compared to that obtained by  
201 using Luminex as stated above, although the set of samples used was slightly different since  
202 not all samples were from individuals with a PCR test done.

### 203 **Highly imbalanced technical and clinical performance for ELISA**

204 Considering the results based on seropositivity by any of the isotypes included in the  
205 immunoassays (**Table 3**), the calculation of technical performance metrics resulted in a  
206 highly imbalanced performance for ELISA, with 96% SE at the expense of a 22% SP. As for  
207 the clinical performance, the NPV reached 87% while the PPV was 51%.

208 When prevalence of infection is low, the PPV of a test strongly relies on a high SP. For  
209 example, given a 95% SE and 5% prevalence, a decrease in SP from 100% to 95% would  
210 result in PPV dropping from 100% to 50%. On the contrary, in a scenario of 95% SE and  
211 20% prevalence, a decrease in SP from 100% to 95% would result in a less steep fall of PPV  
212 from 100% to 83% (25). Conversely, changes in SE within the same context of prevalence  
213 do not affect so markedly the PPV and NPV.

214 In the case of ELISA, the low SP and PPV that we report here has important implications if  
215 this test is to be used in hospitals for their screenings. In particular, a 51% PPV implies that  
216 almost half of the people with a positive serological test would have not had passed the  
217 disease. Therefore, besides the overestimation of exposure to the virus, this would have an  
218 impact on the behavior of the people. Although people with positive serological tests are  
219 advised to keep the security measures, it is likely that they get a feeling of (false) protection  
220 and expose themselves more easily to the virus, increasing the chances of infection. In  
221 addition, false positive diagnosis may lead to unnecessary treatment and psychological  
222 distress. To avoid false positive results and their implications, if more sensitive and specific

223 tests are not available, the pretest probability of infection should be taken into account when  
224 interpreting the results. In the case of serological tests, this includes symptomatology,  
225 contact with COVID-19 confirmed cases, previous history of COVID-19, presence of a PCR  
226 positive test and probability of alternative diagnosis (26).

227 Other reports have evaluated the performance of ELISA IgG and IgM/A from Vircell and have  
228 demonstrated diverse performances. Regarding IgG SE, different studies report the following  
229 ranges of: 65% (20), 86% (23), 13-93% (27), 36-93% (22), and 71-100% (21). The SE  
230 increased with days since onset of symptoms and disease severity (21,22,27). In our case,  
231 the SE for IgG does not reach the highest value reported by any of these papers.

232 A limitation of this study was the impossibility to stratify by days since onset of symptoms due  
233 to the small sample size. Ideally, performance validation should be done stratifying by days  
234 since onset of symptoms due to the kinetics of antibody production, which is delayed with  
235 respect to the onset of the infection. This is especially relevant in the case of IgG, which is  
236 the last immunoglobulin to develop during the course of an immune response. Therefore, the  
237 performance of a test highly depends on the time passed since the onset of infection, which  
238 can be monitored by the onset of symptoms or time since positivity of PCR in asymptomatic  
239 cases. In fact, our Luminex assay and others have demonstrated that performance reaches  
240 excellent levels at >10 o >14 days since onset of symptoms (6,21,22,27). Therefore, IgG SE  
241 assessment in this report would probably be higher had we stratified by days since onset of  
242 symptoms.

243 Concerning IgG SP, the same studies report the following ranges: 53% (22), 90% (23), 83-  
244 95% (21), 96% (20) and 97% (27). None of these values are as high as the 99% SP reported  
245 here, although most of them reach a considerably high SP.

246 With reference to IgM/A, the reported SE are as follows: 76-96% (22), 29-100% (27) and  
247 77% (20). In this case, SE also increased with days since onset of symptoms and disease  
248 severity (22,27). The SE that we report here for IgM/A is concordant with the highest levels of  
249 those results. As for the SP, only one study reports a relatively high SP of 83% (20), while  
250 the other two inform a SP of 23% (22) and 46% (27). These values are not as low as what

251 we report here but also show a very poor performance due to an elevated number of false  
252 positive samples. In fact, IgM is well-known for being a source of false positive results in  
253 immunoassays for many other infectious diseases due to its high non-specific reactivity,  
254 caused by cross-reactivity with other pathogens and the formation of rheumatoid factor (28).  
255 However, the latter is solved in the ELISA IgM/A from Vircell by the use of an IgG sorbent  
256 that removes rheumatoid factor complexes.

257 One explanation for the disagreement observed in some cases could be the source of  
258 biological samples. One study has reported an unsatisfactory performance of an  
259 immunochromatographic IgM/IgG rapid test in pregnant women due to an elevated false  
260 positive rate, and argue that the complexity of the immunological changes during pregnancy  
261 might be the underlying reason (24). Additionally, detection of cross-reactive antibodies  
262 generated by other coronaviruses or infectious diseases has been described and could be a  
263 source of false positive results not only for IgM (14,22).

264 In conclusion, we show a very low SP for the ELISA IgM/A compared to the high values  
265 reported by Vircell. In addition, the SE for the ELISA IgG was also lower than expected,  
266 although this value would probably be higher if only samples with >14 days since onset of  
267 symptoms were considered. Our results stress the need for highly specific and sensitive  
268 assays and external validation of diagnostic tests with different sets of samples.

## 269 **ACKNOWLEDGEMENTS**

270 We thank the Biobanks of Fundació Sant Joan de Déu, Clínic-IDIBAPS and Sant Pau for  
271 valuable management of samples, and the Centre for Genomic Regulation in Barcelona for  
272 the analysis of nasopharyngeal samples and the provision of the S protein. We are indebted  
273 to the nursing staff at Hospital Clínic and to the patients for their generous donation, to  
274 Fundació Glòria Soler for its support to the COVIDBANK initiative and to the HCB-IDIBAPS  
275 Biobank for the biological human samples and data procurement. We are grateful to F.  
276 Krammer for donation of RBD protein.

277 **FUNDING**

278 This study was partially funded by the KidsCorona Child and Mother COVID-19 OpenData  
279 and Biobank Initiative from Hospital Sant Joan de Déu (Stavros Niarchos Foundation,  
280 Santander Foundation and others), “LaCaixa” Foundation, Sant Pau Research Institute,  
281 ISGlobal and Fundació Privada Daniel Bravo Andreu, Barcelona, Spain. Development of  
282 SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for  
283 Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. L. I. work  
284 was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science &  
285 Innovation.

286 **REFERENCES**

- 287 1. Winter AK, Hegde ST. The important role of serology for COVID-19 control. *Lancet*  
288 *Infect Dis.* 2020 Jul;20(7):758–9.
- 289 2. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al.  
290 Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A  
291 Narrative Review. *Ann Intern Med* [Internet]. 2020/06/04. 2020 Sep 15;173(6):450–60.  
292 Available from: <https://pubmed.ncbi.nlm.nih.gov/32496919>
- 293 3. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. *Nat*  
294 *Rev Immunol.* 2020 Jul;20(7):392–4.
- 295 4. U.S. Food and Drug Administration (FDA). Important Information on the Use of  
296 Serological (Antibody) Tests for COVID-19 - Letter to Health Care Providers [Internet].  
297 Available from: [https://www.fda.gov/medical-devices/letters-health-care-  
298 providers/important-information-use-serological-antibody-tests-covid-19-letter-health-  
299 care-providers](https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers)
- 300 5. Kobokovich A, West R, Gronvall G. Serology-Based Tests for COVID19 [Internet].  
301 Baltimore, MD: The Johns Hopkins Center for Health. 2020. Available from:  
302 <https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology->

- 303 based-tests-for-COVID-19.html
- 304 6. Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly sensitive  
305 and specific multiplex antibody assays to quantify immunoglobulins M, A and G  
306 against SARS-CoV-2 antigens. *J Clin Microbiol.* 2020;01731–20.
- 307 7. Vircell Microbiologists. ELISA solution as an aid in the diagnosis of COVID-19  
308 [Internet]. Available from: [https://en.vircell.com/media/filer\\_public/e4/99/e499a112-  
309 4208-45b0-9bca-540540797ab7/covid-19\\_elisa\\_en\\_pme100-0620.pdf](https://en.vircell.com/media/filer_public/e4/99/e499a112-4208-45b0-9bca-540540797ab7/covid-19_elisa_en_pme100-0620.pdf)
- 310 8. Crovetto F, Crispi F, Llurba E, Figueras F, Gómez-Roig MD, Gratacós E.  
311 Seroprevalence and presentation of SARS-CoV-2 in pregnancy. Vol. 396, *Lancet*  
312 (London, England). England; 2020. p. 530–1.
- 313 9. García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G,  
314 Talavera B, et al. Neurological Comorbidity Is a Predictor of Death in Covid-19  
315 Disease: A Cohort Study on 576 Patients [Internet]. Vol. 11, *Frontiers in Neurology* .  
316 2020. p. 781. Available from:  
317 <https://www.frontiersin.org/article/10.3389/fneur.2020.00781>
- 318 10. Trigo J, García-Azorín D, Planchuelo-Gómez Á, Martínez-Pías E, Talavera B,  
319 Hernández-Pérez I, et al. Factors associated with the presence of headache in  
320 hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study.  
321 *J Headache Pain* [Internet]. 2020;21(1):94. Available from:  
322 <https://doi.org/10.1186/s10194-020-01165-8>
- 323 11. Roca-Ginés J, Torres-Navarro I, Sánchez-Arráez J, Abril-Pérez C, Sabalza-Baztán O,  
324 Pardo-Granell S, et al. Assessment of Acute Acral Lesions in a Case Series of  
325 Children and Adolescents During the COVID-19 Pandemic. *JAMA Dermatology*  
326 [Internet]. 2020 Sep 1;156(9):992–7. Available from:  
327 <https://doi.org/10.1001/jamadermatol.2020.2340>
- 328 12. Crovetto F, Crispi F, Llurba E, Pascal R, Larroya M, Trilla C, et al. Impact of SARS-  
329 CoV-2 Infection on Pregnancy Outcomes: A Population-Based Study. *Clin Infect Dis*  
330 *an Off Publ Infect Dis Soc Am.* 2021 Feb;

- 331 13. DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME. The placenta, transfer of  
332 immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. *Crit*  
333 *Rev Toxicol* [Internet]. 2012 Mar 1;42(3):185–210. Available from:  
334 <https://doi.org/10.3109/10408444.2011.653487>
- 335 14. Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N, et al.  
336 Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-  
337 CoV-2: utility and limitations in seroprevalence and immunity studies. *Transl Res.*  
338 2021 Jan 1;2020.12.19.20248551.
- 339 15. Ben-Hur H, Gurevich P, Elhayany A, Avinoach I, Schneider DF, Zusman I. Transport  
340 of maternal immunoglobulins through the human placental barrier in normal  
341 pregnancy and during inflammation. *Int J Mol Med.* 2005 Sep;16(3):401–7.
- 342 16. Vivanti AJ, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Do Cao J, et al.  
343 Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* [Internet].  
344 2020;11(1):3572. Available from: <https://doi.org/10.1038/s41467-020-17436-6>
- 345 17. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, et  
346 al. Performance of six SARS-CoV-2 immunoassays in comparison with  
347 microneutralisation. *J Clin Virol* [Internet]. 2020/06/15. 2020 Aug;129:104512.  
348 Available from: <https://pubmed.ncbi.nlm.nih.gov/32563180>
- 349 18. Nicol T, Lefevre C, Serri O, Pivert A, Joubaud F, Dubée V, et al. Assessment of  
350 SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of  
351 three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and  
352 one rapid lateral flow immunoassay (NG Biotech). *J Clin Virol* [Internet]. 2020/06/15.  
353 2020 Aug;129:104511. Available from: <https://pubmed.ncbi.nlm.nih.gov/32593133>
- 354 19. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six  
355 high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol* [Internet]. 2020/06/01.  
356 2020 Aug;129:104480. Available from: <https://pubmed.ncbi.nlm.nih.gov/32505777>
- 357 20. Gutiérrez-Cobos A, Gómez de Frutos S, Domingo García D, Navarro Lara E, Yarci  
358 Carrión A, Fontán García-Rodrigo L, et al. Evaluation of diagnostic accuracy of 10


- 359 serological assays for detection of SARS-CoV-2 antibodies. *Eur J Clin Microbiol Infect*  
360 *Dis* [Internet]. 2020 Nov 24;1–7. Available from:  
361 <https://pubmed.ncbi.nlm.nih.gov/33236268>
- 362 21. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance of  
363 different SARS-CoV-2 IgG antibody tests. *J Med Virol* [Internet]. 2020 Oct  
364 1;92(10):2243–7. Available from: <https://doi.org/10.1002/jmv.26145>
- 365 22. Cota G, Freire ML, de Souza CS, Pedras MJ, Saliba JW, Faria V, et al. Diagnostic  
366 performance of commercially available COVID-19 serology tests in Brazil. *Int J Infect*  
367 *Dis* [Internet]. 2020 Dec 1;101:382–90. Available from:  
368 <https://doi.org/10.1016/j.ijid.2020.10.008>
- 369 23. Speletas M, Kyritsi MA, Vontas A, Theodoridou A, Chrysanthidis T, Hatzianastasiou S,  
370 et al. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the  
371 Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and  
372 Patients' Management. *Front Immunol* [Internet]. 2020 Dec 23;11:609242. Available  
373 from: <https://pubmed.ncbi.nlm.nih.gov/33424863>
- 374 24. Fabre M, Ruiz-Martinez S, Monserrat Cantera ME, Cortizo Garrido A, Beunza Fabra  
375 Z, Peran M, et al. SARS-CoV-2 immunochromatographic IgM/IgG rapid test in  
376 pregnancy: A false friend? *Ann Clin Biochem* [Internet]. 2020 Nov 27;4563220980495.  
377 Available from: <https://doi.org/10.1177/0004563220980495>
- 378 25. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. *BMJ* [Internet].  
379 2020;369. Available from: <https://www.bmj.com/content/369/bmj.m1808>
- 380 26. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden  
381 problems and costs. *Lancet Respir Med* [Internet]. 2020 Dec 1;8(12):1167–8.  
382 Available from: [https://doi.org/10.1016/S2213-2600\(20\)30453-7](https://doi.org/10.1016/S2213-2600(20)30453-7)
- 383 27. Coste AT, Jatou K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of  
384 SARS-CoV-2 serological tests with different antigen targets. *J Clin Virol* [Internet].  
385 2020/11/17. 2021 Jan;134:104690. Available from:  
386 <https://pubmed.ncbi.nlm.nih.gov/33253926>

387 28. Woods CR. False-Positive Results for Immunoglobulin M Serologic Results:  
388 Explanations and Examples. J Pediatric Infect Dis Soc [Internet]. 2013 Mar 1;2(1):87–  
389 90. Available from: <https://doi.org/10.1093/jpids/pis133>

## 390 **Figures and tables**

391 **Figure 1. Classification of samples by ELISA and Luminex immunoassays for specific**  
392 **IgG, IgM and IgA.** The categories in the X-axis refer to the classification of the ELISA assay  
393 (negative or positive). The Y-axis indicates the Luminex assay result in  $\log_{10}$  transformed  
394 median fluorescence intensity (MFI). The seropositivity cutoff is shown in dashed lines (mean  
395 plus 3 SD of pre-pandemic samples). The color classification in concordant (black) vs.  
396 discordant (grey) sample results between Luminex and ELISA tests is based on the  
397 combination of all antigens within each isotype for Luminex. That is, seropositivity and  
398 seronegativity was calculated per each immunoglobulin with the combination of all antigens  
399 from the Luminex assay, and those were compared with the ELISA result to subsequently  
400 define concordant and discordant samples between tests. The figure illustrates the lower  
401 specificity of the ELISA assay for IgM/A (elevated number of false positives) compared to the  
402 Luminex IgA and IgM assays, and the higher sensitivity of the IgG Luminex for the detection  
403 of positive samples that had been classified as negative by ELISA.





404

• Concordant samples • Discrepant samples

405 **Table 1. Sample size and classification of samples according to their biological origin**

406 **and ELISA results.**

	Mother (N= 241)	Cord (N= 42)	Total (N= 283)
<b>IgG-, IgA/M-</b>	23	0	23
<b>IgG+, IgA/M+</b>	22	0	22
<b>IgG-, IgA/M+</b>	123	3	126
<b>Prepandemic</b>	73	39	112

407 **Table 2. Classification of samples by ELISA and Luminex immunoassays for specific**  
408 **IgG, IgM and IgA and percentage of agreement between the tests.** The table shows the  
409 number of samples classified by the two tests taking into account specific IgG, IgM and IgA  
410 against any of the antigens included in the Luminex multiplex panel or the combination of all  
411 of them. Concordant samples are those classified as negative (LM- E-) or positive (LM+ E+)  
412 by both tests, while discrepant samples are those with opposite results in both tests (LM+ E-  
413 and LM- E+). The percentages of agreement were calculated by dividing the concordant  
414 positive samples (LM+ E+) or concordant negative samples (LM- E-) by the total of samples  
415 that tested positive (LM+ E+, LM+ E-, LM-E+) or negative (LM- E-, LM+ E-, LM-E+) in at least  
416 one of the tests, respectively. LM: Luminex, E: ELISA.

Isotype	Antigen	LM - E -	LM - E +	LM + E -	LM + E +	Positive agreement	Negative agreement
IgG	N FL	142	10	1	18	62.07%	92.81%
	N CT	130	5	13	23	56.10%	87.84%
	S	132	1	11	27	69%	91.67%
	S2	142	1	1	27	93.10%	98.61%
	RBD	133	1	10	27	71.05%	92.36%
	Combination	121	1	22	27	54.00%	84.03%
IgM	N FL	25	122	0	24	16.44%	17.01%
	N CT	25	139	0	7	4.79%	15.24%
	S	25	127	0	19	13.01%	16.45%
	S2	24	134	1	12	8.22%	15.19%
	RBD	25	132	0	14	9.59%	15.92%
	Combination	24	112	1	34	23.29%	17.65%
IgA	N FL	25	121	0	25	17.12%	17.12%
	N CT	25	133	0	13	8.90%	15.82%
	S	22	119	3	27	18.49%	15.60%
	S2	23	115	2	31	21.23%	16.67%
	RBD	23	121	2	25	17.12%	15.97%
	Combination	22	102	3	44	30.14%	17.74%

417

418 **Table 3. Performance of ELISA based on Luminex diagnostic as gold standard.** The  
 419 analysis included samples from mothers (N=168) and cord (N=3). The section of “All  
 420 isotypes” refers to the performance based on seropositivity by any of the three isotypes. FN:  
 421 False negative; FP: False positive, TN: True negative; TP: True positive; SE: Sensitivity; SP:  
 422 Specificity, PPV: Positive predictive value; NPV: Negative predictive value.

<b>Isotype</b>	<b>FN</b>	<b>FP</b>	<b>TN</b>	<b>TP</b>	<b>Total</b>	<b>SE (%)</b>	<b>SP (%)</b>	<b>PPV(%)</b>	<b>NPV(%)</b>
<b>IgG</b>	22	1	121	27	171	55	99	96	85
<b>IgM</b>	1	112	24	34	171	97	18	23	96
<b>IgA</b>	3	102	22	44	171	94	18	30	88
<b>All isotypes</b>	3	73	20	75	171	96	22	51	87

423